Real-World data aims to guide next steps for colorectal cancer patients
NCT ID NCT07263178
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study observes 1000 patients with metastatic colorectal cancer whose first chemotherapy stopped working. Researchers will track which second-line treatments doctors choose and how long patients live or stay cancer-free. The goal is to understand real-world treatment patterns and outcomes, not to test a new drug.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this study could help doctors choose better second-line treatments for metastatic colorectal cancer, potentially improving survival and quality of life.
- What could go wrong
- This is an observational study, not a test of a new treatment. It only collects data from routine care, so it cannot prove which treatment is best. Results may not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Samsung Medical Center
RECRUITINGSeoul, South Korea
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can delivering cancer drug directly to the liver shrink tumors?
- Blood biomarkers could replace invasive biopsies for colorectal cancer monitoring
- One dose may not fit all: blood tests could tailor cancer drug dosing
- Can a Two-Drug combo outsmart resistant colorectal cancer?
- Can a pill boost the immune system to fight Hard-to-Treat cancers?
- Can a Triple-Drug rechallenge tame colorectal cancer?